Clinical trials: Sensory System Agents
Parkinson Disease
TMS-related Measures as Biomarker of Cognitive Impairment in PD
The goal of the present study is to explore the diagnostic and prognostic value of neurophysiological biomarkers obtained through paired-pulse Transcranial Magnetic Stimulation (TMS) techniques in individuals affected by…
- Trial name
- SAI-PD22 (NCT06835595)
- Testing
- Transcranial Magnetic Stimulation
- Where
- 3 sites in Italy
- Volunteers
- 52 people
- Sponsor
- Azienda Sanitaria Universitaria Integrata del Trentino
Lumbar Spinal Fusions
Pregabalin for the Treatment of Pain After Posterior Spinal Fusions
Acute pain management is challenging in patients after spinal fusions, particularly since most have taken analgesics for prolonged periods before choosing the surgical alternative.
- Trial name
- NCT01366196
- Testing
- Pregabalin 150 mg
- Where
- United States
- Volunteers
- 86 people
- Sponsor
- Hospital for Special Surgery, New York
Depressive Disorder, Treatment-Resistant, Stress Disorders, Post-Traumatic
Ketamine Infusions for PTSD and Treatment-Resistant Depression
The relationship between depression and trauma is well established. Co-occuring depression and post-traumatic stress disorder (PTSD) are associated with more severe symptoms and lower levels of functioning.
- Trial name
- NCT02577250
- Testing
- Ketamine
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Minneapolis Veterans Affairs Medical Center
Breast Cancer, Colorectal Cancer
Chemotherapy-Induced Peripheral Neuropathy Survey
The goal of this research study is to learn more about pain and other symptoms that patients may experience while receiving chemotherapy treatment with platinum agents, taxanes, and/or bortezomib.
- Conditions
- Breast Cancer, Colorectal Cancer, Myeloma, Chemotherapy-induced Peripheral Neuropathy
- Trial name
- NCT01016028
- Testing
- Questionnaire, Sensory Tests, Interview
- Sponsor
- M.D. Anderson Cancer Center
Treatment Resistant Depression, Major Depressive Disorder
Oral Aspirin + Ketamine as Adjunct to Oral Antidepressant Therapy for Depression
The purpose of this study is to assess the effects of simultaneous administration of oral aspirin and oral ketamine as a therapeutic for those with Treatment Resistant Depression.
- Conditions
- Treatment Resistant Depression, Major Depressive Disorder, Analgesia, Ketamine
- Trial name
- NCT05615948
- Testing
- VTS-K
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Theresa Jacob, PhD, MPH
Methamphetamine Use Disorder
Behavioral Effects of Drugs (Inpatient): 40 [Methamphetamine, Methylphenidate, Duloxetine]
This study will evaluate the behavioral effects of methamphetamine during maintenance on placebo, duloxetine, methylphenidate and duloxetine combined with methylphenidate using sophisticated human laboratory methods.
- Trial name
- NCT04178993
- Testing
- Methamphetamine, Methylphenidate, Duloxetine
- Where
- 2 sites in United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Craig Rush
Advanced Solid Tumours
A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced Cancer
The study is investigating efficacy, safety and tolerability of DNA-damage Response Agents (or Combinations), in participants with advanced/metastatic solid malignancies whose tumours contain molecular alterations
- Trial name
- NCT04564027
- Testing
- Ceralasertib
- Where
- 18 sites in United States, France and 1 more
- Volunteers
- 54 people
- Sponsor
- AstraZeneca
Cancer Pain, Cancer
PARASTOP - Paracetamol With Strong Opioids
Current guidelines recommend all people with cancer-related pain should be prescribed paracetamol, even those receiving high doses of strong pain killers (opioids) such as morphine.
- Trial name
- PARASTOP (NCT05051735)
- Testing
- Paracetamol
- Where
- 15 sites in Italy, Norway and 2 more
- Volunteers
- 204 people
- Sponsor
- Oslo University Hospital
Multiple Myeloma, Neoplasm, Plasma Cell
Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma
This study will find the maximum tolerated dose (MTD) of CYNK-001 which contain NK cells derived from human placental CD34+ cells and culture-expanded. CYNK-001 cells will be given post Autologous Stem Cell Transplant (ASCT).
- Conditions
- Multiple Myeloma, Neoplasm, Plasma Cell, Neoplasms by Histologic Type, Neoplasms
- Trial name
- NCT04309084
- Testing
- CYNK-001
- Where
- 4 sites in United States
- Volunteers
- 29 people
- Sponsor
- Celularity Incorporated